P Leif Bergsagel

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Molecular pathogenesis and a consequent classification of multiple myeloma
    P Leif Bergsagel
    Comprehensive Cancer Center, Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    J Clin Oncol 23:6333-8. 2005
  2. ncbi request reprint MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
    Esther Masih-Khan
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    Blood 108:3465-71. 2006
  3. pmc Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
    P Leif Bergsagel
    Mayo Clinic Scottsdale, Comprehensive Cancer Center and Division of Hematology Oncology, Scottsdale, AZ, USA
    Blood 106:296-303. 2005
  4. pmc Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
    Joseph R Mikhael
    Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 119:4391-4. 2012
  5. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
  6. pmc Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
    Yuan Xiao Zhu
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Blood 118:4771-9. 2011
  7. pmc Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity
    Rodger E Tiedemann
    Mayo Clinic, Comprehensive Cancer Center, Division of Hematology and Oncology, Scottsdale, Arizona, USA
    J Clin Invest 118:1750-64. 2008
  8. pmc Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:640-5. 2011
  9. pmc Clonal competition with alternating dominance in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 120:1067-76. 2012
  10. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010

Detail Information

Publications48

  1. ncbi request reprint Molecular pathogenesis and a consequent classification of multiple myeloma
    P Leif Bergsagel
    Comprehensive Cancer Center, Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    J Clin Oncol 23:6333-8. 2005
    ....
  2. ncbi request reprint MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
    Esther Masih-Khan
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    Blood 108:3465-71. 2006
    ..Our observation is the first to directly link an initiating IgH translocation not only to MM-cell growth and survival but also to the disease-associated bone disease...
  3. pmc Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
    P Leif Bergsagel
    Mayo Clinic Scottsdale, Comprehensive Cancer Center and Division of Hematology Oncology, Scottsdale, AZ, USA
    Blood 106:296-303. 2005
    ..However, despite subsequent progression events, these groups have differing gene expression profiles and also significant differences in the prevalence of bone disease, frequency at relapse, and progression to extramedullary tumor...
  4. pmc Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
    Joseph R Mikhael
    Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 119:4391-4. 2012
    ..It is well tolerated with few side effects. CyBorD warrants continued investigation as treatment for AL...
  5. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
    ..This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial...
  6. pmc Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
    Yuan Xiao Zhu
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Blood 118:4771-9. 2011
    ..In summary, CRBN is an essential requirement for IMiD activity and a possible biomarker for the clinical assessment of antimyeloma efficacy...
  7. pmc Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity
    Rodger E Tiedemann
    Mayo Clinic, Comprehensive Cancer Center, Division of Hematology and Oncology, Scottsdale, Arizona, USA
    J Clin Invest 118:1750-64. 2008
    ..These data support targeted repression of cyclin D genes as a therapeutic strategy for human malignancies...
  8. pmc Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:640-5. 2011
    ..CRd is an effective and well-tolerated regimen for upfront therapy of MM with high response rates and excellent 2-year OS, and is suitable for long-term therapy...
  9. pmc Clonal competition with alternating dominance in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 120:1067-76. 2012
    ..With the use of the Vk*MYC genetically engineered mouse model of myeloma we modeled this competition between subclones for predominance occurring spontaneously and with therapeutic selection...
  10. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  11. pmc Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
    P Leif Bergsagel
    Division of Hematology Oncology, Mayo Clinic in Arizona, Scottsdale, AZ 85259, USA
    Blood 121:884-92. 2013
    ..Reviewing available data in high-risk MM from this perspective, it appears that bortezomib has frequently been associated with improved survival, whereas thalidomide maintenance has sometimes been associated with a shorter survival...
  12. pmc Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
    Marta Chesi
    Comprehensive Cancer Center, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA
    Blood 120:376-85. 2012
    ..We predict that combinations of standard agents, histone deacetylase inhibitors, bromodomain inhibitors, and hypoxia-activated prodrugs will demonstrate efficacy in the treatment of relapsed MM...
  13. pmc Molecular pathogenesis of multiple myeloma: basic and clinical updates
    Marta Chesi
    Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Int J Hematol 97:313-23. 2013
    ..Available evidence supports the use of a risk-stratified approach to the treatment of patients with multiple myeloma, with the early and prolonged use of bortezomib particularly in patients with t(4;14) and del 17p...
  14. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  15. pmc AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
    Marta Chesi
    Comprehensive Cancer Center, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Cancer Cell 13:167-80. 2008
    ....
  16. pmc Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
    Jan B Egan
    Division of Hematology Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 120:1060-6. 2012
    ....
  17. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  18. pmc Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia
    Esteban Braggio
    Mayo Clinic, Scottsdale, Arizona 85259 5494, USA
    Cancer Res 69:3579-88. 2009
    ....
  19. pmc MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
    Huadong Pei
    Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Nature 470:124-8. 2011
    ..Thus, we propose that a pathway involving γH2AX-MDC1-MMSET regulates the induction of H4K20 methylation on histones around DSBs, which, in turn, facilitates 53BP1 recruitment...
  20. pmc Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
    Rodger E Tiedemann
    Division of Hematology Oncology, Mayo Clinic Arizona, 13400 Shea Blvd, Scottsdale, AZ 85259, USA
    Blood 115:1594-604. 2010
    ..As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma...
  21. pmc Approach to the treatment of multiple myeloma: a clash of philosophies
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Blood 118:3205-11. 2011
    ....
  22. pmc Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Cancer Cell 12:131-44. 2007
    ..These results highlight the critical importance of the NF-kappaB pathway in the pathogenesis of multiple myeloma...
  23. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
    ..To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma...
  24. pmc Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications
    Wee J Chng
    Department of Hematology Oncology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ, USA
    Blood 113:635-45. 2009
    ..In conclusion, MALT subgroups with distinct pathologic features defined by distinct groups of deregulated genes were identified. These genes could represent novel diagnostic and therapeutic targets...
  25. pmc Many multiple myelomas: making more of the molecular mayhem
    Marta Chesi
    Department of Hematology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Hematology Am Soc Hematol Educ Program 2011:344-53. 2011
    ..These patients should be enrolled in innovative clinical trials. The remaining patients with cyclin D translocations or hyperdiploidy do well with most therapies, and the goal should be to control disease while minimizing toxicity...
  26. ncbi request reprint Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 27:5008-14. 2009
    ..We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma...
  27. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  28. ncbi request reprint Genetics and cytogenetics of multiple myeloma: a workshop report
    Rafael Fonseca
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 64:1546-58. 2004
    ..Areas in need of further study were identified. The study of the genetic aberrations will likely form the platform for targeted therapy for the disease...
  29. ncbi request reprint Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, Arizona, USA
    Cancer Res 67:2982-9. 2007
    ..Furthermore, the signatures that defined these clusters may provide a basis for tailoring treatment to individual patients...
  30. ncbi request reprint Individualizing therapy using molecular markers in multiple myeloma
    P Leif Bergsagel
    Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Clin Lymphoma Myeloma 7:S170-4. 2007
    ..Stem cell transplantation is deferred in patients with high-risk molecular markers, and in all patients, response is followed closely and determines the individual timing and sequence of therapeutic regimens...
  31. pmc The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
    Jotin Marango
    Division of Hematology Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Blood 111:3145-54. 2008
    ....
  32. pmc Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes
    David P Steensma
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 69:7518-23. 2009
    ..These data support involvement of IER3 in the pathobiology of MDS...
  33. pmc Comprehensive identification of somatic mutations in chronic lymphocytic leukemia
    P Leif Bergsagel
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, USA
    Cancer Cell 20:5-7. 2011
    ..Early results for hematopoietic tumors show great promise, but many questions remain to be answered...
  34. ncbi request reprint Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    R A Kyle
    Division of Hematology, Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1121-7. 2010
    ..Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months...
  35. ncbi request reprint Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
    George Mulligan
    Clinical Research Translational Medicine, Millennium Pharmaceuticals Inc, 40 Landsdowne Street, Cambridge, MA 02139, USA
    Blood 109:3177-88. 2007
    ..Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents...
  36. ncbi request reprint Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma
    Elaine M Hurt
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Cell 5:191-9. 2004
    ..The frequent overexpression of c-maf in myeloma makes it an attractive target for therapeutic intervention...
  37. ncbi request reprint Advances in biology of multiple myeloma: clinical applications
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 104:607-18. 2004
    ....
  38. ncbi request reprint Chemotherapy of multiple myeloma: melphalan--40 years old and still going strong
    P Leif Bergsagel
    Weill Medical College of Cornell University, New York, NY, USA
    Biol Blood Marrow Transplant 9:2-3. 2003
  39. ncbi request reprint Bone lesions in molecular subtypes of multiple myeloma
    Davide F Robbiani
    N Engl J Med 351:197-8. 2004
  40. pmc Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
    Jonathan J Keats
    Department of Oncology, University of Alberta and Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada
    Blood 105:4060-9. 2005
    ..In contrast, RE-IIBP is universally dysregulated and also potentially functional in all t(4;14)POS patients irrespective of fibroblast growth factor receptor 3 (FGFR3) expression or breakpoint type...
  41. ncbi request reprint Multiple myeloma: evolving genetic events and host interactions
    W Michael Kuehl
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda Naval Hospital, Maryland 20889 5105, USA
    Nat Rev Cancer 2:175-87. 2002
    ..What causes full-blown myeloma? And can our molecular understanding of this common haematological malignancy be used to develop effective preventive and treatment strategies?..
  42. ncbi request reprint The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression
    Marta Chesi
    Weill Medical College of Cornell University, New York, USA
    Curr Opin Hematol 9:288-93. 2002
    ..However, it remains to be proven if and how dysregulation of FGFR3 or MMSET mediates an early oncogenic process in multiple myeloma...
  43. ncbi request reprint Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma
    P Leif Bergsagel
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Immunol Rev 194:96-104. 2003
    ..We speculate that ectopic cyclin D1 expression without t(11;14) is dependent on tumor-specific interaction with bone marrow stromal cells...
  44. ncbi request reprint Prognostic factors in multiple myeloma: it's in the genes
    P Leif Bergsagel
    Clin Cancer Res 9:533-4. 2003
  45. ncbi request reprint Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
    Suzanne Trudel
    Department of Medicine, Weill Medical College and Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Blood 103:3521-8. 2004
    ..In addition, this represents the validation of a therapeutic target in MM that may benefit patients who have a very poor prognosis with currently available treatments...
  46. ncbi request reprint Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
    W Wei Lynn Wong
    Departments of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Mol Cancer Ther 6:1886-97. 2007
    ..003). These results suggest that statins may be a useful molecular targeted therapy in the treatment of a subset of MM...
  47. pmc FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway
    Sumin Kang
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Cell 12:201-14. 2007
    ..Our findings suggest that FGFR3 mediates hematopoietic transformation by activating RSK2 in a two-step fashion, promoting both the ERK-RSK2 interaction and subsequent phosphorylation of RSK2 by ERK...
  48. ncbi request reprint Osteopontin dysregulation and lytic bone lesions in multiple myeloma
    Davide F Robbiani
    Department of Medicine, Division of Hematology and Medical Oncology, Weill Medical College and Graduate School of Medical Sciences of Cornell University, New York, NY, USA
    Hematol Oncol 25:16-20. 2007
    ..OPN is produced in osteolytic lesions: we propose that MM-derived OPN plays a critical role in bone disease by protecting bone from destruction...